Cadernos de Pós-Graduação em Distúrbios do Desenvolvimento
Print version ISSN 1519-0307On-line version ISSN 1809-4139
Abstract
ZACCARELLI-MAGALHAES, Julia; FUKUSHIMA, André Rinaldi; RICCI, Esther Lopes and SPINOSA, Helenice de Souza. New trends of the ketamine use in depression disorders: implications in the development of progeny. Cad. Pós-Grad. Distúrb. Desenvolv. [online]. 2018, vol.18, n.1, pp.31-46. ISSN 1519-0307. https://doi.org/10.5935/cadernosdisturbios.v18n1p31-46.
NMDA glutamatergic receptors are potential targets for novel therapies for the treatment of depression, with ketamine, an antagonist of such receptors, as one of these therapies. Considering that there is a trend toward an increased clinical use of ketamine as an antidepressant and there is little information on the safety and efficacy of its prolonged use and in perinatal period, this review aims to provide more recent information on the effects of depression on progeny development and the general use of ketamine as a treatment for postpartum depression. For that, a bibliographic survey was conducted in guidelines and journals obtained from the SciELO, PubMed and ScienceDirect databases between the years 2000 and 2017, using the following terms as inclusion criteria: depression, postpartum depression, ketamine, antidepressant and escetamine. The selected studies show that traditional therapy for the treatment of depression during the postpartum period presents risks to the development of the offspring, due to this fact, studies are needed that lead to the development of new therapies for this disease. Ketamine has promising potential for the treatment of depressive disorders in general, including postpartum depression, minimizing the risks to offspring development.
Keywords : Ketamine; Depression; Development; Progeny; Antidepressant.